BioSpace News Archive

9 Meters Biopharma, Inc. announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in a panel presentation and one-on-one investor meetings at the 11th Annual LifeSci Partners Corporate Access Event.

Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, which is scheduled to take place in San Francisco, CA from February 17-19, 2022.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of three new executives to its management team.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda®

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) (Paris:DSY) today announced it will enable CES 2022 attendees to “meet” their virtual twin and see the possibilities that virtual twins of the human body bring to health care, January 5-8, 2022 in Las Vegas.

Aytu BioPharma, Inc. announced that Josh Disbrow, chief executive officer of Aytu, will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference, which will become available for on-demand viewing on Monday, January 10, 2022 at 7:00 a.m. ET.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare Conference.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.